Biovica International AB Class B · OMXSTO:BIOVIC_B
Biovica International AB Class B — Investor Presentation (February 2023)
21 slides from Biovica International AB Class B's investor presentation, February 2023
Slide 1: Treatment Decisions With Greater Confidence
Treatment Decisions With Greater Confidence Company Presentation February 2023 1
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: About the Presenters
About the Presenters Anders Rylander, CEO & Board Member • CEO & main shareholder in Biovica • Co-founder of Axholmen Management Consulting • CTO at ICA AB • Senior Manager at Accenture Anders Morén, CFO • CFO • Executive Director Finance EMEA, Gilead • CFO MSD Sweden • Business Development Manager,
Slide 4: Agenda
Agenda 1. Company & Product 2. Market potential 3. US go-to market plan 4. Summary 4 4
Slide 5: Biovica Overview
Biovica Overview • Founded 2009, based on research performed at Uppsala University • IPO 2017, traded on Nasdaq First North Premier • HQ in Uppsala, lab in San Diego • ISO 13485 certified • DiviTum® TKa CE labeled, FDA 510(k) cleared 5
Slide 6: DiviTum TKa Provides Early Response Indicator of Treatment Effectiveness
DiviTum® TKa Provides Early Response Indicator of the Effectiveness of Treatment For Cancer Patients Imaging diagnostics + Months DiviTum® TKa measures cell proliferation rate for faster evaluation of cancer treatment efficacy. References: http://biovica.com/technology/publications/ 6
Slide 7: 510(k) clearance take-aways
510(k) clearance take-aways • 510(k) clearance for DiviTum® TKa – i.e., Biovica can now legally market DiviTum® TKa in the U.S. • FDA created a unique code, QTE, for DiviTum® TKa • Key-driver to FDA was DiviTum® TKa’s very high NPV (Negative Predictive Value) - i.e., a negative test result assures –
Slide 8: Budget Impact Model Results: Net Savings of 3x the Spend
Budget Impact Model Results: Addition of DiviTum® TKa to Care Would Lead to Net Savings of 3x the Spend • Other monitoring costs: Reduced by Scenario 1: decrease in CT scans, bone scans Changes to monitoring only • 1st line therapy: Reduced usage of CDK 4/6 inhibitors • 2nd line and beyond: small in
Slide 9: Strong Clinical Results and Data for DiviTum TKa Peer-Reviewed & Published
Strong Clinical Results and Data for DiviTum® TKa Peer- Reviewed & Published in Clinical Oncology Journals • 24 published and peer-reviewed Cancer area Patients No of Studies articles with DiviTum® TKa Breast Cancer 1,293 13 • Summary of results from articles: Gastrointestinal 713 4 Lung Cancer 281
Slide 10: Extensive Breast Cancer Study Program
Extensive Breast Cancer Study Program Screening Early breast cancer Locally advanced Metastatic breast cancer High risk Stage I-II Stage III Stage IV BRCA, 2013 Prognostic, 2010 TEX, Prognostic, 2013 CDK neoadjuvant, 2017 ET, Pro, M 2018 Operable BC, SABCS 2019 EFECT, ET, Pro, M 2019 PROMIX, 2021 TR
Slide 11: Agenda
Agenda 1. Company & Product 2. Market potential 3. US go-to market plan 4. Summary 11 11
Slide 12: Geographical Roll-out Plan & Market Potential for DiviTum TKa
Geographical Roll-out Plan & Market Potential for DiviTum® TKa in HR+ Metastatic Breast Cancer 1. US LAUNCH CLINICAL USAGE & UPTAKE Market potential: 200-350 mUSD TOTAL MARKET POTENTIAL 2. EU-5 & NORDICS CLINICAL USAGE & UPTAKE 400-700 Market potential: 150-250 mUSD mUSD 3. JAPAN CLINICAL USAGE & UP
Slide 13: Biovica Commercial Roadmap
Legend Biovica Commercial Roadmap 15% of market potential 50% of market potential MARKET POTENTIAL BREAST CANCER LAUNCHc BUILD REVENUES REALIZE POTENTIAL LAUNCHc BUILD REVENUES REALIZE POTENTIAL 400-700 LAUNCHc BUILD REVENUES REALIZE POTENTIAL METASTATIC mUSD/y LAUNCHc BUILD REVENUES REALIZE POTENTI
Slide 14: Agenda
Agenda 1. Company & Product 2. Market potential 3. US go-to market plan 4. Summary 14 14
Slide 15: Successful High Value Dx Companies Follow the CLIA Lab Go-To-Market Strategy
Successful High Value Dx Companies Follow the CLIA Lab Go-To-Market Strategy Managing critical success factors position the company for long-term sustainable growth: 1. Stakeholder Relationships - patient, physician and payer 2. Reimbursement – insurance coverage, value and utilization 3. Access – a
Slide 16: US Sales – Commercial Readiness and Targeting
US Sales – Commercial Readiness and Targeting Maximize Salesforce Readiness Sophisticated Targeting Methodology High Density Payer Treatment Reimbursement Geographies Mix • Initiated recruitment process and identified highly Influential Rx Data - High experienced sales candidates Oncology Key Volume
Slide 17: Reimbursement Strategy
Reimbursement Strategy Public Insurance Value-Based Collaborations Private Insurance At launch we will: At launch we will: At launch we will: • Engage our Medicare • Engage hospitals and general • Bill using a miscellaneous Current Administrative Contractor (MAC) reference lab to establish client Pr
Slide 18: US Senior Management
US Senior Management Warren Cresswell, President of the Americas • 25-years of Diagnostic Experience in Medical Device (IVD 510(k) & PMA), CLIA Lab (LDT), and Pharma • Built Dx Orgs, Developed & Launched High Value Multi-Analyte Algorithm Based Dx Assays, and Implemented Effective Reimbursement Stra
Slide 19: High Performing Sales Team To Join In Time For Launch
High Performing Sales Team To Join In Time For Launch South Sales Director West Sales Director Central Sales Director East Sales Director West Mkt Access Sr. Dir. East Mkt Access Sr. Dir. • 20+ yrs. in Medical Sales • 20+ yrs. in Medical Sales • 20+ yrs. in Medical Sales • 15+ yrs. in Medical Sales
Slide 20: Agenda
Agenda 1. Company & Product 2. Market potential 3. US go-to market plan 4. Summary 20 20
Slide 21: Summary & Milestones
Summary & Milestones • Measures cell proliferation from a simple blood sample • DiviTum® TKa addresses an important clinical unmet need • DiviTum® TKa is supported by cancer KOL’s and scientific collaborators globally • Market potential > $2 billion for monitoring of metastatic cancer (key indicatio
Biovica International — Investor Presentation (February 2023) on 6ix